Skip to Content
Merck
All Photos(1)

Documents

SML2608

Sigma-Aldrich

CSRM617 Hydrochloride

≥98% (HPLC)

Synonym(s):

(2,3,4-Trihydroxyphenyl-methylidene)-hydrazino-2-amino-3-hydroxy-1-propanone hydrochloride, 2-Amino-3-hydroxy-N′-(2,3,4-trihydroxybenzylidene)propanehydrazide hydrochloride, 2-[(2,3,4-trihydroxyphenyl)methylene] serinehydrazide hydrochloride (1:1)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H13N3O5 · HCl
CAS Number:
1353749-74-2
Molecular Weight:
291.69
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

OC1=C(C=CC(O)=C1O)C=NNC(C(CO)N)=O.Cl

Related Categories

Biochem/physiol Actions

CSRM617 is an ONECUT2 (OC2) inhibitor that directly targets OC2 HOX domain (KD = 7.43 μM) and disrupts OC2 target genes promoter binding. CSRM617 blocks OC2-dependent prostate cancer growth in cultures (IC50 = 4-50 μM; 48 h) via apoptosis induction (fold of untreated annexin V population = 2.3/10 μM, 3.5/20 μM; 22Rv1) and exhibits in vivo efficacy against metastases as well as the growth of established 22Rv1 tumor in mice in vivo (50 mg/kg/day ip.).

Signal Word

Warning

Hazard Statements

H317,H319,H341,H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Muta. 2 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Irene Zamora et al.
Cellular oncology (Dordrecht, Netherlands) (2024-05-31)
Tumor heterogeneity complicates patient treatment and can be due to transitioning of cancer cells across phenotypic cell states. This process is associated with the acquisition of independence from an oncogenic driver, such as the estrogen receptor (ER) in breast cancer
Mirja Rotinen et al.
Nature medicine, 24(12), 1887-1898 (2018-11-28)
Treatment of prostate cancer (PC) by androgen suppression promotes the emergence of aggressive variants that are androgen receptor (AR) independent. Here we identify the transcription factor ONECUT2 (OC2) as a master regulator of AR networks in metastatic castration-resistant prostate cancer

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service